Unlocking the therapeutic potential of nature. 

Green Leaf Librede.jpg


Nature has provided us with a wide range of high value therapeutic compounds and Librede’s mission is to tap into these useful compounds in environmentally and economically sustainable ways. Librede’s yeast-based synthetic biology platform enable access to these compounds unlocking the therapeutic potential of nature.



Librede has developed a yeast based cannabinoid production and drug discovery platform to create chemical compounds that target the endocannabinoid system (ECS). Focusing on the natural cannabinoids found in the cannabis plant, Librede’s modular technology enables large scale production of natural cannabinoids in a more economic and environmentally sustainable way. Fermentation enables low cost production of ultra-low abundant cannabinoids that are not accessible through agricultural production at an industrial scale. This technology allows access to these therapeutic compounds in a way that is environmentally friendly using no fertilizers or pesticides and less water, land and energy.

Welcome to the future of cannabinoid production!

Librede Modular Cannabinoids from Sugar.png

Looking toward nature for our health.


Librede Plant 3.jpg


Librede currently offers compounds involved in the biosynthesis of cannabinoids and terpenes found in the cannabis plant. Products include: olivetol, olivetolic acid, divarinol, divarinic acid, limonene, geraniol, myrcene, and caryophyllene. Contact Librede to ask about specifics.


Librede has a great deal of expertise in genetic engineering, synthetic biology, and the endocannabinoid system. Librede has the capabilities to produce rare compounds and assist in formulation design. Contact Librede with your special request.

What’s next:

Librede will offer pure cannabinoids as active pharmaceutical ingredients (APIs). These compounds can be used to create therapeutic products.

Librede’s technology allows for personalized formulations to be created by our customers. Since we can control the precise chemical mixture of our oils customers can specify what ratio of cannabinoids they would like in their final products to achieve the desired nutraceutical or pharmaceutical effect. For example if a customer wants a specific mixture of cannabinoids (e.g. a  5:2:1:1:1 mixture of CBD:CBN:THCA:CBGA) Librede can create that mixture on demand. 



Librede Plant 2.jpg

Dr. Jason Poulos - Chief Executive Officer

Dr. Jason Poulos, Ph.D. received his B.S in Mechanical Engineering from the University of California, San Diego and a Ph.D. in Biomedical Engineering from University of California, Los Angeles in 2009. After UCLA, Dr. Poulos founded Librede with Dr. Jacob Schmidt to develop and market artificial biological systems. Dr. Poulos led the technical and commercialization efforts as Chief Technology Officer until late 2011 when he became CEO of Librede. Dr. Poulos has an extensive technical background and, along with Dr. Farina, developed the world’s first yeast based cannabinoid production platform. As CEO of Librede, Dr. Poulos has managed multiple million dollar biotechnology projects and is responsible for the commercialization of Librede’s cannabinoid production and drug development platform.

Dr. Anthony Farina - Chief Scientific Officer

Dr. Anthony Farina, Ph.D. received his B.S in Biochemistry from the University of California, Riverside and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Diego. Dr. Farina joined Librede as Director of Research in 2012, where he led the development of multiple engineered cell lines as well as the creation of Librede’s yeast based cannabinoid production platform. Dr. Farina's interdisciplinary expertise in chemistry, synthetic biology, and metabolic engineering is at the core of Librede’s product development.


Dr. Jacob Schmidt, Ph.D

Dr. Jacob Schmidt, Ph.D. is Professor in the Department of Bioengineering at the University of California, Los Angeles where he focuses on artificial biological systems and nano/bio hybrid devices. Dr. Schmidt co-founded Librede with Dr. Poulos in 2009 and is a recognized leader in artificial biology technologies with over 60 publications and patents in the field.

Dr. Todd Peterson, Ph.D

Dr. Todd Peterson, Ph.D. has been a integral part of commercialization several biotechnology products. He is an expert in large scale fermentation, synthetic biology, and building biotech-based companies.

Mr. Steve rothman, esq

Mr. Steve Rothman is Librede's lead counsel and has over three decades of experience in start-ups with expertise in initial company formation, mergers, acquisitions, and licensing.